<DOC>
	<DOCNO>NCT01176097</DOCNO>
	<brief_summary>The purpose study investigate safety tolerability AZD5658 follow ascend single oral dos Type 2 Diabetics . It also estimate maximum tolerated dose .</brief_summary>
	<brief_title>To Assess Safety , Tolerability , Pharmacokinetics/Pharmacodynamics Effect Fasting After Single Oral Doses AZD5658 Type 2 Diabetes</brief_title>
	<detailed_description>This randomize , single-blind , placebo-controlled , single-center , phase 1 study ass safety , tolerability , pharmacokinetics , pharmacodynamics effect fast single ascend oral dos AZD5658 type 2 diabetes mellitus patient .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Patients must nonchildbearing potential . Body mass index great equal 19 less equal 40 kg/m2 Patients confirm Type 2 Diabetes diagnosis least 1 year treat Metformin Clinically significant illness clinically relevant trauma within 2 week first administration IP Participation another clinical study last 30 day prior enrollment Significant cardiovascular event within last 6 month prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>First man study evaluate AZD5658 Type 2 Diabetics .</keyword>
	<keyword>Effect fast</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
</DOC>